Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 76

1.

Expression of corticotropin releasing hormone in malignant melanoma.

Funasaka Y, Sato H, Ichihashi M.

Ann N Y Acad Sci. 1999 Oct 20;885:391-3. No abstract available.

PMID:
10816672
[PubMed - indexed for MEDLINE]
2.

The expression of corticotropin-releasing hormone in melanoma.

Sato H, Nagashima Y, Chrousos GP, Ichihashi M, Funasak Y.

Pigment Cell Res. 2002 Apr;15(2):98-103.

PMID:
11936276
[PubMed - indexed for MEDLINE]
3.

Gene transfer of pro-opiomelanocortin prohormone suppressed the growth and metastasis of melanoma: involvement of alpha-melanocyte-stimulating hormone-mediated inhibition of the nuclear factor kappaB/cyclooxygenase-2 pathway.

Liu GS, Liu LF, Lin CJ, Tseng JC, Chuang MJ, Lam HC, Lee JK, Yang LC, Chan JH, Howng SL, Tai MH.

Mol Pharmacol. 2006 Feb;69(2):440-51. Epub 2005 Nov 3.

PMID:
16269535
[PubMed - indexed for MEDLINE]
Free Article
4.

Effect of intracerebroventricular administration of the octadecaneuropeptide on the expression of pro-opiomelanocortin, neuropeptide Y and corticotropin-releasing hormone mRNAs in rat hypothalamus.

Compère V, Li S, Leprince J, Tonon MC, Vaudry H, Pelletier G.

J Neuroendocrinol. 2003 Feb;15(2):197-203.

PMID:
12535162
[PubMed - indexed for MEDLINE]
5.
6.

Serotonergic stimulation of corticotropin-releasing hormone and pro-opiomelanocortin gene expression.

Jørgensen H, Knigge U, Kjaer A, Møller M, Warberg J.

J Neuroendocrinol. 2002 Oct;14(10):788-95.

PMID:
12372003
[PubMed - indexed for MEDLINE]
7.

Possible alternate splicing or initiation of the pro-opiomelanocortin gene in lymphocytes.

Galin FS, Leboeuf RD, Blalock JE.

Int J Neurosci. 1990 Apr;51(3-4):171-2. No abstract available.

PMID:
2279861
[PubMed - indexed for MEDLINE]
8.

Molecular and transgenic studies of the corticotropin-releasing hormone gene.

Majzoub JA, Muglia LJ, Martinez C, Jacobson L.

Ann N Y Acad Sci. 1995 Dec 29;771:293-300. No abstract available.

PMID:
8597407
[PubMed - indexed for MEDLINE]
9.

Corticotropin-releasing hormone and pro-opiomelanocortin gene expression in female monkeys with differences in sensitivity to stress.

Centeno ML, Sanchez RL, Reddy AP, Cameron JL, Bethea CL.

Neuroendocrinology. 2007;86(4):277-88. Epub 2007 Oct 11.

PMID:
17934253
[PubMed - indexed for MEDLINE]
10.

Melanocyte development and malignant melanoma.

Goding CR.

Forum (Genova). 2000 Jul-Sep;10(3):176-87. Review.

PMID:
11007928
[PubMed - indexed for MEDLINE]
11.

Oestrogenic regulation of pro-opiomelanocortin, neuropeptide Y and corticotrophin-releasing hormone mRNAs in mouse hypothalamus.

Pelletier G, Li S, Luu-The V, Labrie F.

J Neuroendocrinol. 2007 Jun;19(6):426-31.

PMID:
17388940
[PubMed - indexed for MEDLINE]
12.

Corticotropin-releasing hormone (CRH) expression and protein kinase A mediated CRH receptor signalling in an immortalized hypothalamic cell line.

Kasckow J, Mulchahey JJ, Aguilera G, Pisarska M, Nikodemova M, Chen HC, Herman JP, Murphy EK, Liu Y, Rizvi TA, Dautzenberg FM, Sheriff S.

J Neuroendocrinol. 2003 May;15(5):521-9.

PMID:
12694378
[PubMed - indexed for MEDLINE]
13.

Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs.

Carlson KW, Nawy SS, Wei ET, Sadée W, Filov VA, Rezsova VV, Slominski A, Quillan JM.

Anticancer Res. 2001 Mar-Apr;21(2A):1173-9.

PMID:
11396159
[PubMed - indexed for MEDLINE]
14.

Murine models of malignant melanoma.

Tietze MK, Chin L.

Mol Med Today. 2000 Oct;6(10):408-10. Review. No abstract available.

PMID:
11006531
[PubMed - indexed for MEDLINE]
15.
16.

NF-kappaB participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene.

Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C.

J Biol Chem. 2004 Mar 19;279(12):10837-40. Epub 2004 Jan 6.

PMID:
14711817
[PubMed - indexed for MEDLINE]
Free Article
17.

Corticotropin-releasing hormone or dexamethasone regulates rat proopiomelanocortin transcription through Tpit/Pitx-responsive element in its promoter.

Murakami I, Takeuchi S, Kudo T, Sutou S, Takahashi S.

J Endocrinol. 2007 May;193(2):279-90.

PMID:
17470519
[PubMed - indexed for MEDLINE]
Free Article
18.

Ablation of pituitary pro-opiomelanocortin (POMC) cells produces alterations in hypothalamic POMC mRNA levels and midbrain mu opioid receptor binding in a conditional transgenic mouse model.

Zhou Y, Unterwald EM, Ho A, LaForge KS, Yuferov VP, Kreuter J, Sirianni MJ, Allen RG, Kreek MJ.

J Neuroendocrinol. 2001 Sep;13(9):808-17.

PMID:
11578531
[PubMed - indexed for MEDLINE]
19.

Investigation of the corticotropin-releasing hormone-proopiomelanocortin axis in various skin tumours.

Kim MH, Cho D, Kim HJ, Chong SJ, Lee KH, Yu DS, Park CJ, Lee JY, Cho BK, Park HJ.

Br J Dermatol. 2006 Nov;155(5):910-5.

PMID:
17034518
[PubMed - indexed for MEDLINE]
20.

Neuropeptide Y immunoreactivity and corticotropin-releasing hormone mRNA level are increased in the hypothalamus of mouse bearing a human oral squamous cell carcinoma.

Lee JH, Cha MJ, Choi SH, Hwang SJ, Kim DG, Jahng JW.

Neuropeptides. 2004 Dec;38(6):345-50.

PMID:
15567470
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk